Commentary|Videos|April 2, 2024
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer
Author(s)Christian Marth, MD, PhD
Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.
Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5